CClinicalTrials.gg
Sign In
TerminatedNCT02080741DiatolepsyUpdated Feb 9, 2026

Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile

An interventional study of Blood sample of 12 ml in Patients With Type 1 or Type 2 Diabetes and Patients With a Type A or B Behaviour Profile, sponsored by Centre Hospitalier Universitaire Dijon. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Centre Hospitalier Universitaire Dijon · Not applicable, Interventional, and Other

Why this study was terminated
lack of inclusion
Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of 50 patients according to their behaviour type, and their adaptation to different factors of stress encountered in their lives:

  • the first group will consist of patients with a characteristic Type A behaviour profile, that is to say patients with a "proactive, impatient" behaviour pattern
  • the second group will consist of patients with a characteristic Type B behaviour profile that is to say patients with a "calm, slow" behaviour pattern The objective is to know if the different behaviour patterns are associated with distinct biological markers likely to influence the evolution of the diabetes.

Participation in this study will be approximately 1h30, patients will participate ONCE ONLY:

  1. they will answer simple questions about their disease and then complete 3 questionnaires each with 14 items.
  2. they will meet a clinical psychologist for an interview lasting approximately 45 minutes recorded on an audio recorder. The consultation will be used to seek links between the psyche and the disease.
  3. they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the morning.
02

Conditions studied

  • Patients With Type 1 or Type 2 Diabetes
  • Patients With a Type A or B Behaviour Profile
03

In context

Diabetes Mellitus, Type 2

9,357 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 57 is below the median of 80 across 7,523 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who have provided written informed consent
  • Patients with type 1 or type 2 diabetes
  • Patient admitted for a consultation, as out or in-patients to the Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU
  • Patient > 18 years
  • Patient with either a characteristic Type A behaviour profile (Bortner > 210), or a characteristic Type B behaviour profile (Bortner\<154)

Exclusion criteria

Exclusion Criteria:

  • Persons not covered by national health insurance
  • Adults under guardianship or wards of court or not intellectually independent
  • Patients without diabetes
  • Patients with a mixed A/B behaviour profile (154\< Bortner score \<210)
  • Pregnant or breast-feeding women
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Other
    Type A behaviour profile

    Other: Blood sample of 12 ml

  • Other
    Type B behaviour profile

    Other: Blood sample of 12 ml

Interventions

  • OtherBlood sample of 12 ml
06

What researchers measure

Primary outcomes

  1. Telomere length

    Time frame: Baselines

Secondary outcomes

  1. Level of expression of candidate genes

    Time frame: Baselines

Other outcomes

  1. Complications of diabetes (Nephropathy, Retinopathy, Neuropathy, Coronaropathy)

    Time frame: Baselines

  2. Scores on psychiatric/psychological scales

    Time frame: Baselines

  3. Analysis of the specific psychological interview EMIC

    Time frame: Baselines

07

Study locations

1 site
  • CHU de DIJON
    Dijon, 21079, France
08

References and documents

Publications

  • Chauvet-Gelinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebai A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Verges B. Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. Diabetes Metab. 2019 Dec;45(6):582-585. doi: 10.1016/j.diabet.2018.11.005. Epub 2018 Nov 23. PubMed 30476653 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02080741
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Mar 6, 2014
Start date
Sep 23, 2014
Primary completion
May 29, 2018
Last update
Feb 9, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus, Type 2→

Other studies from this sponsor

Centre Hospitalier Universitaire Dijon

Start the discussion